Edition:
United Kingdom

Immune Pharmaceuticals Inc (IMNP.OQ)

IMNP.OQ on NASDAQ Stock Exchange Capital Market

0.71USD
8:59pm GMT
Change (% chg)

$-0.07 (-8.99%)
Prev Close
$0.78
Open
$0.78
Day's High
$0.78
Day's Low
$0.70
Volume
109,295
Avg. Vol
157,012
52-wk High
$5.02
52-wk Low
$0.70

Chart for

About

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its... (more)
No analyst recommendations are available for .

Overall

Beta: 2.17
Market Cap(Mil.): $15.02
Shares Outstanding(Mil.): 10.58
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Immune Pharmaceuticals reports Q3 results

* Immune Pharmaceuticals announces third quarter 2017 financial results and provides a corporate update

15 Nov 2017

BRIEF-Immune Pharmac prices $18 mln public offering

* Immune Pharmaceuticals Inc announces pricing of $18,000,000 public offering of convertible preferred stock and warrants

19 Oct 2017

BRIEF-Immune Pharmaceuticals announces positive results from ongoing phase 2 trial of bertilimumab

* Immune Pharmaceuticals announces positive results from ongoing phase 2 trial of bertilimumab in bullous pemphigoid

27 Sep 2017

BRIEF-Immune Pharmaceuticals appoints Daniel Teper as CEO for Cytovia

* Immune Pharmaceuticals provides research and development and business update and summary of recent financial highlights.

28 Aug 2017

BRIEF-Immune Pharmaceuticals files for non-timely 10-Q

* Immune Pharmaceuticals Inc files for non-timely 10-Q - sec filing Source text: (http://bit.ly/2fFbJWp) Further company coverage:

14 Aug 2017

BRIEF-Immune Pharmaceuticals provides update on plan to spin-off Cytovia

* Immune Pharmaceuticals provides update on plan to implement a spin-off of Cytovia into a separate publicly traded oncology company

19 Jul 2017

BRIEF-Immune Pharma announces filing of patent protecting use of ceplene

* Immune Pharmaceuticals announces filing of a patent protecting use of ceplene (histamine dihydrochloride) in hematologic cancers

13 Jul 2017

BRIEF-Cytovia Inc enters agreement with Pint Pharma for licensing of Ceplene in Latin America

* Cytovia Inc, Immune Pharmaceuticals’ oncology subsidiary, enters into a definitive agreement with Pint Pharma for the licensing and commercialization of Ceplene® in Latin America

11 Jul 2017

BRIEF-Immune Pharmaceuticals' oncology unit announces additional clinical trial results on the efficacy of Ceplene in combination with low-dose IL-2 in patients with acute myeloid leukemia

* Immune Pharmaceuticals' oncology subsidiary, Cytovia, announces additional clinical trial results on the efficacy of Ceplene® in combination with low-dose IL-2 in patients with acute myeloid leukemia, recently published in leukemia, a leading Hematology Journal

05 Jul 2017

BRIEF-Immune Pharmaceuticals files for offering of upto 1.4 mln shares

* Immune Pharmaceuticals Inc files for offering of upto 1.4 million shares of common stock by the selling stockholders - SEC filing Source text: (http://bit.ly/2t04Ovb) Further company coverage:

30 Jun 2017

Competitors

Earnings vs. Estimates